Sign In  |  Register  |  About Burlingame  |  Contact Us

Burlingame, CA
September 01, 2020 10:18am
7-Day Forecast | Traffic

  • Search Hotels in Burlingame

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Durect Corp (NQ: DRRX )

0.4164 +0.0226 (+5.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 27, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 930,353
Open 0.3900
Bid (Size) 0.3956 (5)
Ask (Size) 0.4298 (10)
Prev. Close 0.3938
Today's Range 0.3850 - 0.4196
52wk Range 0.3601 - 1.845
Shares Outstanding 227,764,019
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Executives Buy Around $17M Of 5 Penny Stocks
The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their... 
Via Benzinga
Earnings Outlook For Durect
Durect (NASDAQ:DRRX) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Durect will report... 
Via Benzinga

Performance

YTD
-57.29%
-57.29%
1 Month
-11.40%
-11.40%
3 Month
-39.09%
-39.09%
6 Month
-59.18%
-59.18%
1 Year
-75.21%
-75.21%

More News

Read More
55 Biggest Movers From Friday
Via Benzinga
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Via Benzinga
53 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Earnings Scheduled For March 7, 2022
Via Benzinga
Preview: Durect's Earnings
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (March 6-12): Quiet Week On Tap With Earnings Season Reaching It Final Leg
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
Via Benzinga
The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal
Via Benzinga
The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street
Via Benzinga
The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
Via Benzinga
Topics Stocks
Exposures US Equities
The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Burlingame.com & California Media Partners, LLC. All rights reserved.